Clinical Trial Update: Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing secukinumab in rheumatoid arthritis patients with inadequate response to anti-TNF therapy. The study was terminated and results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2016-07-21